Recruiting studies: Platinum Resistant Ovarian High Grade Serous Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 · 27 location(s) · National Cancer Institute (NCI) · NCT04633239 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366 Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
Phase 1/Phase 2 · 1 location(s) · Xing Xie · NCT04518501 Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Phase 2 · 1 location(s) · Emory University · NCT05998135 Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Res
Phase 1 · 7 location(s) · National Cancer Institute (NCI) · NCT04585958 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo
Phase 1 · 14 location(s) · National Cancer Institute (NCI) · NCT05950464

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.